The non-pathogenic human parvovirus, adeno-associated virus (AAV) is helper virus-dependent. However, it integrates into the cellular genome in the absence of its helper viruses. Therefore it could become a useful vector for gene therapy. Previous studies and our own results have shown that 40 to 80 % of adults are seropositive for AAV and that seroconversion occurs during the first few years of life, but little is known about the route of natural infection with the virus. We used the polymerase chain reaction to detect the AAV-2 genome and identify AAV sequences within peripheral blood leukocytes (PBLs). We could detect AAV in PBLs of two of 55 healthy blood donors, and two of 16 haemophilic patients. AAV DNA replication and viral protein production in PBLs propagated in tissue culture were also examined. AAV DNA replicated very efficiently in the presence of helper adenovirus, but capsid proteins were produced at a lower level and the yield of infectious virus was very low. Our findings prove that in vivo infection of PBLs occurs, and that PBLs could mediate the spread of AAV infection tO different body tissues.
The adeno-associated viruses (AAVs) belong to the genus Dependovirus of the family Parvoviridae (Siegl et al., 1985) . AAV can replicate in cell culture only on coinfection with a helper virus, either an adenovirus (Ad) (Atchison et al., 1965) or a herpesvirus [herpes simplex virus (HSV)] (Buller et al., 1981) . In the absence of a helper virus, AAV particles can penetrate the cell nucleus and viral sequences can integrate into the cellular genome to establish a latent infection (Berns et al., 1975; Cheung et al., 1980; Hoggan et al., 1972; Tratschin et al., 1985) . AAV infects a wide range of animal species, from birds to man. Seroepidemiological studies have shown that 40 to 70~ of the adult population carry antibodies to the virus (Blacklow et al., 1968; Sprecher-Goldberger et al., 1971) .
AAV inhibits the replication as well as the oncogenicity and transforming abilities of both Ad and HSV, and of bovine papillomavirus. The AAV rep gene products have been shown to inhibit the promoter/enhancer elements of a variety of cellular genes (reviewed by Berns, 1990) and recently it has been demonstrated that the virus can inhibit the growth of cells derived from malignant human tumours (Bantel-Schaal, 1990 ). Although ubiquitous, AAV has not been associated with any disease or pathological condition.
Recently, site-specific integration of AAV DNA has been demonstrated (Kotin & Berns, 1989; Kotin et al., 1990) , increasing the attractiveness of the virus as a potential vector for gene therapy. Despite extensive investigation and the accumulation of molecular information, detail of the natural history of in vivo infection with the virus remains limited.
We investigated whether blood leukocytes could be naturally infected with AAV, and whether they could support latent or productive infection. Two strategies were adopted. (i) A polymerase chain reaction (PCR) was adjusted for the sensitive detection of the AAV genome and applied for the identification of AAV sequences within peripheral blood leukocytes (PBLs); (ii) AAV replication and virus production in PBLs propagated in tissue culture were studied. The prevalence of antibodies to AAV in the studied populations was also investigated.
The PCR was performed as described by Saiki et al. (1985) using 25 pmol of each of two primers derived from the AAV-2 genome: AI+A2, A4+A5, A7+A8 or A1 +A5 [A1, nucleotides (nt) 156 to 174; A2, nt 402 to 383; A4, nt 708 to 727; A5, nt 998 to 981 ; A7, nt 4131 to 4150; A8, nt 4500 to 4480 in the AAV genome]. None of these primers is homologous to the AAV rep gene sequences recently found in association with the human herpesvirus 6 (HHV-6) genome by Thomson et al. (1991) .
The PCR was first applied to the analysis of DNA extracted from the latently AAV-2-infected cell line D5 clone 7374 (Berns et al., 1975; Cheung et al., 1980 Laughlin et al., 1983) . Fig. 1 (a) shows agarose gel electrophoresis of the PCR products. In addition to the expected bands, some additional non-specific bands were revealed by ethidium bromide staining, especially in samples lacking AAV sequences ( Fig. 1 a, lanes 2 and 5). The specificity of amplification was assessed by hybridization to pAV2 D N A labelled by nick translation. A single strong band of the expected size was seen when AAV sequences were present, whereas no signal was detected in the AAV-negative controls ( Fig. 1 b) .
To verify the specificity of the amplification further, an unequal PCR reaction was performed, and followed by direct sequencing of the amplified segments. Comparison of the sequences showed complete agreement with the published AAV-2 sequences. The sensitivity of the test was examined by amplification of D N A from minute cell samples, as described by Li et al. (1988) . D5 cells were serially diluted with PBS, boiled in water for 10 min and the lysates were subjected to 45 cycles of PCR amplification using primers A4 and A5. Following electrophoresis and hybridization, it was possible to detect AAV sequences in samples containing between two and six cells.
We next screened D N A samples extracted from PBLs of 71 individuals, 55 healthy blood donors and 16 haemophilia patients, who are frequently exposed to blood products and thus are more susceptible to various infections. PBLs were obtained from healthy blood donors or haemophilia patients after informed consent. PBLs were collected from 10 to 20 ml peripheral blood after separation by Ficoll/Hypaque gradient centrifugation and D N A was extracted as described. Primers A4 and A5 were used for the PCR. In a typical test, 200 ng D N A was subjected to 40 cycles of the amplification reaction. Taking precautions to avoid contamination, the work was performed according to the instructions of Kwok & Higuchi (1989) , and at least two independent tests were done on each sample. Of the 55 healthy blood donor and the 16 haemophilia patients samples, two of each were positive in the PCR. In the second part of the study PBL samples from healthy volunteers were cultured in R P M I 1640 medium supplemented with 15~o foetal calf serum, 5 gg/ml phytohaemagglutinin and 50 units/ml interleukin 2. Molecularly cloned, purified A A V -2 stocks, free of contaminating A d (Yakobson et al., 1989) , and plaquepurified Ad-2 ( A T C C ) were used for infection. PBLs (4.5 x 105) in culture were washed twice with serum-free medium and then infected with 200 infectious units (i.u.)/cell AAV-2 and 20 i.u./cell Ad-2 in 200 gl serumfree medium for 2 h at 37°C. The infection was terminated by washing the cells three times with serumfree medium. Control groups were infected with AAV-2 or Ad-2 alone or mock-infected with serum-free medium. Immediately after the infection the cells were replated in 10 ml medium containing 1 0~ serum. Half was harvested immediately, and the other 5 ml after 8 days. From each 5 ml sample, 1 ml was kept for virus titration and antigen determination. From the remainder 4 ml, viral D N A was prepared by the method of Hirt (1967) with modifications to preserve s s D N A (Tratschin et al., 1984a) .
The results of one replication experiment are illustrated in Fig. 3 . Viral D N A extracted from the cells was separated on a 1 ~ agarose gel, transferred to a nylon m e m b r a n e and hybridized with 32p-labelled p A V 2 probe. N o A A V D N A could be detected in the mock-or Ad-infected cells (Fig. 3, lanes 2 to 5) AAV protein synthesis in PBLs and HeLa cells was assessed using an ELISA for AAV capsid proteins. An antigen capture assay was performed using rabbit anti-AAV capsid IgG for coating the plates, 100 ~tl of infected culture suspensions or AAV stock virus, and guinea-pig anti-AAV serum for virus detection. Incubation was for 2 h at 37 °C or overnight at 4 °C, followed by extensive washing with PBS-Tween. Alkaline phosphatase conjugated to goat anti-guinea-pig IgG (Sigma A/7644) was used for detection of antibodies. The amount of AAV capsid protein in the culture suspensions was calibrated using the pure AAV stock as a standard.
PBL extracts were prepared 8 days after infection, whereas the HeLa cells were collected 4 days after infection (before complete c.p.e.). After 8 days the amount of AAV protein in the PBL lysates was about threefold that present on day 1, whereas in HeLa cells, 4 days after infection the amount was about 18-fold larger than that on day 1. Despite extensive viral DNA replication and moderate protein synthesis, there was little evidence for production of infectious virus. The virus titres on days 1 and 8 after infection were measured using the dispersed cell assay, essentially as described by Yakobson et al. (1989) . Several dilutions of each cell culture supernatant were used to infect 25 000 HeLa cells in the presence of Ad-2 and in parallel with increasing concentrations of pure AAV stock of known titre. Cells were harvested 48 h after infection, immobilized and denatured on nylon filters, hybridized to 32p-labelled pAV2 DNA and counted. The virus titre in each sample was determined according to a calibration curve obtained from the pure AAV stock. The ratios between virus titres between days 1 and 8 were 1.3, 0-5 and 0.4 in three successive experiments. Thus, the yield of infectious virus was at best very low. As the amount of the capsid proteins in PBLs was low compared to that of the control, a possible explanation for the low infectious virus yields could be an insufficient amount of capsid proteins or some inhibition of virion particle maturation.
Finally, an ELISA was developed by us to test the prevalence of antibodies to AAV in serum. The conditions were first determined for rabbit anti-AAV serum, then modified for use with human test serum. Briefly, wells of microtitre plates were coated with CsC1 gradient-purified AAV-2 particles, incubated overnight at 4 °C, then washed, blocked with 1 ~ BSA in PBSTween for 1 h at 37 °C, and washed again. Human serum (diluted 1 : 100 with 2~ BSA in PBS-Tween) was added and incubated for 2 h at 37 °C or overnight at room temperature. Alkaline phosphatase-conjugated goat anti-human IgG (Bio-Makor 3420) was used for detection of antibodies.
The cutoff values were calculated using the positive/ negative (P/N) ratio method described by Tijssen (1985) , and established further by Anderson et al. (1986) and Schwartz et al. (1988) . Two groups of positive and negative control sera were established based on the complement fixation (CF) test. Specificity and sensitivity were determined by titration of the antigen and antibodies in ELISA. We established a range for negative control samples which varied between an absorbance of 0.03 and 0.13 over many runs. A sample representing the mean value of the negative group (N) and one representing that of the positive group were chosen as negative and positive controls, respectively, for the routine tests. Based on our titration experiments, test sera (P) were regarded as positive if the P/N ratio was ~> 2.0. Routinely, blood serum samples were diluted 1 : 100 and tested in triplicate. Two groups of volunteers were tested, healthy blood donors and haemophiliacs. In the haemophiliac group (males only) we found 15 of 18 tested to be seropositive (83~); 75~ of healthy male blood donors (27 of 36) and 87~o of the female control group (40 of 46) were seropositive. Thus, the prevalence of antibodies against AAV was similar in the groups tested (average 82 ~). These results suggest that ELISA is more sensitive than the CF test used previously (Sprecher-Goldberger et al., 1971 ) and is more comparable with the neutralization test used by Blacklow et al. (1968) . A larger sample of sera would enable a probability distribution analysis of the population, which may reveal subpopulations within the group of positive sera.
To summarize, our analysis using PCR demonstrated the presence of the AAV genome in the peripheral blood of some individuals. The frequency of positive samples among normal blood donors (two of 55) was lower than that among haemophiliacs (two of 16), but the number of samples in each group was too small to endow a strong statistical significance. Larger groups will have to be tested to determine whether haemophilia patients do carry the virus more frequently than normal individuals. The frequency of virus detection in the PBLs was much lower than the seroprevalence of the virus in both populations.
The successful in vitro infection of lymphocytes with AAV supports the PCR findings by demonstrating infection of this subset of blood cells, although virus production was low. The finding of AAV sequences in PBLs suggests that this virus, like many other infectious agents, can be transmitted by transfusion of blood products. However, we do not know whether the acquisition of this virus has any adverse effects on the recipient.
The number of independent isolations of AAV has so far been limited, but the finding that normal individuals carry the virus in PBLs indicates that systematic efforts to characterize many different AAV genomes and their integration sites are necessary. This is particularly important in the light of recent reports of a selective integration site for the AAV-2 genome in a specific segment of chromosome 19 (Kotin et al., 1990) . A recent finding (Thomson et al., 1991) demonstrating the acquisition of AAV-2 rep gene sequences by HHV-6 also supports our data and emphasizes the role that AAV may play in mixed infections of human.
The non-pathogenic nature of AAV and the possible specificity of its integration in vivo make it an attractive candidate for use as a vector for gene therapy (Hermonat & Muzyczka, 1984; LaFace et al., 1988; Lebkowski et al., 1988; Tratschin et al., 1984b) . Our finding that lymphocytes can be infected with the virus and support its replication in the presence of a helper virus is highly relevant to this potential application.
